RxDoctor Payments Data

Raymond Stewart, MD

Family Medicine · Stratford, CTNPI 1891794848

Payments from drug & device makers

$2,630in general payments, 2019–2025

Across 115 payments — averaging $22.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$779
  • Boehringer Ingelheim$566
  • AstraZeneca$300
  • Pfizer$202
  • Lilly USA, LLC$187
  • Ironwood Pharmaceuticals, Inc$164
  • plus $432 from 7 others

What the payments were for

  • Food & beverage$2,59599%
  • Education$351%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,630 in reported general payments places this provider in the 80th percentile of 588 family medicine providers in Connecticut.

See all family medicine providers in Connecticut

Medicare billing

Part B allowed, 2024
$305
Medicare patients
23
Services billed
32

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin106$140,994
LinzessLinaclotide120$112,944
OzempicSemaglutide104$102,835
JanumetSitagliptin Phos/Metformin Hcl90$100,088
EliquisApixaban97$64,240
TradjentaLinagliptin51$51,338
FarxigaDapagliflozin Propanediol63$49,669
JanuviaSitagliptin Phosphate30$35,646
JentaduetoLinagliptin/Metformin Hcl37$29,387
MounjaroTirzepatide24$26,147
SymbicortBudesonide/Formoterol Fumarate79$20,547
TrulicityDulaglutide19$18,825
VraylarCariprazine Hcl12$17,454
XareltoRivaroxaban16$12,202
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$10,460

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta, Jentadueto$566$221,720194 claims
MerckJanumet, Januvia$58$135,735120 claims
AbbVieLinzess, Vraylar$119$130,399132 claims
Novo NordiskOzempic$779$102,835104 claims
AstraZenecaFarxiga, Symbicort$300$70,216142 claims
PfizerEliquis$202$64,24097 claims
Lilly USA, LLCMounjaro, Trulicity$187$44,97243 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 588 family medicine providers in Connecticut.

Other family medicine in Stratford

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →